- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04925713
IFx-Hu2.0 for the Treatment of Patients With Skin Cancer
Phase 1 Trial of IFx-Hu2.0 to Evaluate Safety in Patients With Skin Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a multi-site, open-label, interventional, prospective, phase 1 trial to assess safety and tolerability of IFx-Hu2.0 in patients with basal cell carcinoma, squamous cell carcinoma, or cutaneous melanoma.
A total of approximately one hundred (100) male and/or female adult patients (greater than or equal to 18 years old), of any ethnicity and race, with at least one cutaneous melanoma, squamous cell carcinoma, or basal cell carcinoma lesion accessible for direct injection, who meet all inclusion and no exclusion criteria, will be eligible for enrollment and treatment with IFx-Hu2.0.
Enrollees will receive IFx-Hu2.0 as a single intralesional injection at a single time point. The target dose will be 100 μg of plasmid DNA per lesion injected at a final dose volume of 200 μL per lesion. The injected lesion will be completely excised at the follow-up visit four weeks later and will be biopsied for confirmation of diagnosis and for the establishment of a pathological response baseline peripheral blood will be collected from these patients prior to treatment administration and at the follow-up visit four weeks later. These samples will be used to perform complete blood counts (CBC) and clinical chemistry tests. A urine sample will be obtained for urinalysis for protein and blood at the same frequency. Blood samples will be drawn for immune response evaluation as well.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Expanded Access
Contacts and Locations
Study Locations
-
-
Florida
-
Brandon, Florida, United States, 33716
- Moore Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Ability to receive intralesional injections
- Male or female, aged ≥ 18 years
- Histologically confirmed cutaneous squamous cell carcinoma, or basal cell carcinoma with accessible lesions (based on archival tissue or new tissue biopsy for histological confirmation)
- Life expectancy of at least 24 weeks at the time of screening
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Must have measurable disease greater than 3 mm
- At least one injectable lesion
Adequate organ function as defined below (Note: these screening laboratory tests must be obtained within two weeks prior to the baseline visit, Day 0):
10.1. Hemoglobin (Hb) >10 g/dL 10.2. Absolute Neutrophil Count (ANC) >1,500 cells/mcL 10.3. Platelet Count (PLT) >75,000/mcL 10.4. Prothrombin Time (PT) or International Normalized Ratio (INR) ≤1.5 times the institutional ULN unless patient is receiving anticoagulant therapy as long as PT or INR is within therapeutic range of the intended use of anticoagulants.
10.5. Activated Partial Thromboplastin Time (aPTT) ≤1.5 times the institutional ULN unless patient is receiving anticoagulant therapy as long as aPTT is within therapeutic range of the intended use of anticoagulants.
10.6. Serum Creatinine (SCr) ≤1.5 times the institutional ULN 10.7. Total Bilirubin ≤1.5 times the institutional ULN 10.8. Aspartate Aminotransferase (AST) ≤3 times the institutional ULN 10.9. Alanine Aminotransferase (ALT) ≤3 times the institutional ULN 10.10. Lactate Dehydrogenase (LDH) ≤2 times the institutional ULN 10.11. Alkaline Phosphatase (ALP) ≤2.5 times the institutional ULN 10.12. Gamma GT (GGT) ≤2.5 times the institutional ULN
- Lymphocyte count ≥500,000 cells/mL
- For females of reproductive potential: must have a negative urine or serum pregnancy test result within 24 hours prior to receiving IFx-Hu2.0; must use highly effective contraception (e.g.,licensed hormonal or barrier methods) for at least one month prior to screening and agreement to use such a method during study participation and for an additional 26 weeks after the end of study treatment
- For males of reproductive potential: use of barrier method or other methods to ensure effective contraception with partner
Exclusion Criteria:
- Concurrent participation in any other clinical trial
- Inability to consent for self
- Lesions on scalp with bone erosions must not be selected as injection sites for IFx-Hu2.0
- Life expectancy of fewer than 24 weeks at the time of screening
- Prior systemic anti-cancer treatment within three weeks from start of treatment (Day 0)
- Treatment with any investigational product within the three weeks preceding injection
- Concurrent chemotherapy or biological therapy. Concurrent radiotherapy is allowed as long as it is not the same site as the injected lesion.
- Current treatment with systemic immunosuppressive corticosteroid (greater than 10 mg of daily prednisone) doses or other immunosuppressants such as those needed for solid organ transplants. Medications needed to treat conditions such as reactive airway disease are not excluded.
- Is pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 26 weeks after the last dose of trial treatment
- Immunizations for encapsulated bacteria were not given for patients who have undergone a splenectomy
- Serious underlying medical or psychiatric conditions, active infections requiring the use of antimicrobial drugs, or active bleeding that would make the subject unsuitable or unable to participate in the study
- Active Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS) or Hepatitis B/C. Patients with treated HIV/AIDS or Hepatitis B/C with no evidence of active infection may be enrolled
- History of organ allograft transplantation
- Presence of any uncontrolled and significant medical or psychiatric condition which would interfere with trial safety assessments
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion
One hundred (100) patients will receive 0.1 mg of IFx-Hu2.0 injected intratumorally in a single lesion at a single time point and be followed-up 28 days thereafter.
|
The investigational drug product IFx-Hu2.0 is composed of the drug substance pAc/emm55 (pDNA) complexed with the two excipients in vivo-jetPEI® (linear polyethylenimine), a transfection reagent, and dextrose, a pDNA/polyethylenimine complex stabilizer. Therapeutic Classification:
Route of Administration:
Mechanism of Action:
Physiological Effect:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Adverse Events
Time Frame: 28 days post injection
|
Rate of Adverse Events reported per Common Terminology Criteria for Adverse Events (CTCAE) v5.0
|
28 days post injection
|
Number of Patients who completed the trial
Time Frame: 28 days post injection
|
Number of Patients who completed the trial per protocol without major deviations
|
28 days post injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Pathological Complete Response (pCR)
Time Frame: Definitive surgery 4 weeks post treatment
|
Rate of patients with complete absence of residual viable tumor in the treated tumor bed on histological assessment of fully excised lesion
|
Definitive surgery 4 weeks post treatment
|
Rate of Major Pathological Response (mPR)
Time Frame: Definitive surgery 4 weeks post treatment
|
Rate of patients with ≤10% of residual viable tumor present in the treated tumor bed on histological assessment of fully excised lesion
|
Definitive surgery 4 weeks post treatment
|
Rate of Partial Pathological Response (pPR)
Time Frame: Definitive surgery 4 weeks post treatment
|
Rate of patients with ≤50% of residual viable tumor present in the treated tumor bed on histological assessment of fully excised lesion
|
Definitive surgery 4 weeks post treatment
|
Rate of Pathological Non-Response (pNR)
Time Frame: Definitive surgery 4 weeks post treatment
|
Rate of patients with >50% of residual viable tumor present in the treated tumor bed on histological assessment of fully excised lesion
|
Definitive surgery 4 weeks post treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SC 2020-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Basal Cell Carcinoma
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell Carcinoma | BCC | BCC - Basal Cell Carcinoma | Basal Cell CancerUnited States
-
MediWound LtdRecruitingNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
University of MiamiCompletedNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
Christopher ZacharyRecruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
University Hospital, BordeauxCompletedLocally Advanced Basal Cell Carcinoma | Metastatic Basal Cell CarcinomaFrance
-
Seton Healthcare FamilyUniversity of Texas at Austin; Dell Medical School at The University of Texas...WithdrawnBasal Cell Carcinoma (BCC) | Squamous Cell Carcinoma (SCC)
-
Biofrontera Bioscience GmbHActive, not recruitingSuperficial Basal Cell CarcinomaUnited States
-
Maastricht University Medical CenterRadboud University Medical Center; Catharina Ziekenhuis EindhovenCompletedSuperficial Basal Cell CarcinomaNetherlands
-
Maastricht University Medical CenterActive, not recruitingNodular Basal Cell CarcinomaNetherlands
-
Kavita SarinNational Institutes of Health (NIH); Medivir; American Skin AssociationCompletedSkin Basal Cell CarcinomaUnited States
Clinical Trials on IFx-Hu2.0
-
TuHURA Biosciences, Inc.Dana-Farber Cancer Institute; University of Southern California; H. Lee Moffitt... and other collaboratorsActive, not recruitingMerkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Non-Melanoma Skin CancersUnited States
-
Morphogenesis, Inc.H. Lee Moffitt Cancer Center and Research InstituteCompletedCutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
-
TuHURA Biosciences, Inc.AvailableMerkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IV
-
Yale UniversityNational Institute on Drug Abuse (NIDA); VA Connecticut Healthcare SystemCompleted
-
InflaRx GmbHCompletedSystemic Inflammatory Response Syndrome | C.Surgical Procedure; CardiacGermany
-
InflaRx GmbHCompletedHidradenitis SuppurativaGreece
-
InflaRx GmbHIqvia Pty LtdTerminatedGranulomatosis With Polyangiitis (GPA) | Microscopic Polyangiitis (MPA)United States, Canada
-
Ranbaxy Laboratories LimitedCompleted
-
Groupe d'Etude Therapeutique des Affections Inflammatoires...CompletedCrohn's DiseaseFrance
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruitingModerate to Severe Ulcerative ColitisChina